Table 3.

Targeted therapies evaluated in clinical trials for thyroid cancer.

Drug	VEGFR1	VEGFR2	VEGFR3	RET	BRAF	Other	Response; PFS	Citation
Axitinib	X	X	X				31% PR; 18 mos (MTC included)	Cohen et al. [91, 99]
Motesanib	X	X	X	X			14% PR; 9 mos	Sherman et al. [97]
Sorafenib		X	X	X	X		13–32% PR; PFS 10–21 mos	Kloos et al. [86], Gupta-Abramson et al. [87], Cabanillas et al. [88]
Sunitinib	X	X	X	X			28% CR + PR; TTP 13 mos	Carr et al. [93]
Pazopanib	X	X	X	X			49% PR; PFS 12 mos	Bible et al. [94]
Lenvatinib	X	X	X	X		FGFR	50% PR; PFS 13 mos	Sherman et al. [105]
Cabozantinib	X	X		X		c-MET	53% PR; PFS n/a	Cabanillas et al. [101]

PR: partial response, SD: stable disease, TTP: time to progression, PFS: progression-free surivival, n/a: not available, and mos: months.